The global urolithiasis management devices market was valued at USD 2.21 billion by 2030, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 4.9% from 2023 to 2030. The alarming growth in the incidence rate of urinary stones, over the years, is responsible for the advancements in the treatment options. Urolithiasis means formation of stones in the urinary system, mainly including the kidney, ureters, and the bladder. It is a major healthcare concern in the high end countries such as the U.S., Canada, and Germany with a recurrence rate of 50% in most of the cases. European Association of Urology states that it is one of the most common lifestyle disorders with a 10% prevalence rate and requires a systematic treatment approach.
Intracorporeal lithotripsy treatments spot and reduce the stones to smaller pieces with the help of endoscopy. For the disintegration of stones, ultrasound or laser techniques are used to enable the passage of smaller fragments through the urinary system. Furthermore, percutaneous nephrolithotomy is a surgical approach deployed to eliminate larger stones where extracorporeal or intracorporeal lithotripsies prove to be ineffective and typically require a week’s hospitalization.
Get deeper insights, latest developments & key market drivers in the Global Urolithiasis Management Devices Market
Recent Developments
• In July 2022, Calyxo, a company developing technology for kidney stone removal, declared that its USD 32.7 million Series C investment round was closed. California-based Calyxo, with the intention of removing kidney stones without surgery, created the CVAC Aspiration system. It uses irrigation and aspiration to do it.
• In January 2022, the FDA designated Applaud Medical's Acoustic Enhancer technology as a breakthrough product, according to an announcement. Applaud Medical, a San Francisco-based company, created an Acoustic Enhancer technology for use with ureteroscopy with laser lithotripsy (URS-LL) to divide calcium-based urinary stones that are obstructing or that a urologist or other qualified medical professional determines to pose a significant risk of future hindrance and are at least 6mm in diameter but not larger than 20mm.
• In addition, in March 2021, Boston Scientific and a Baring Private Equity Asia (BPEA) unit inked a legally binding agreement for Boston Scientific to pay USD 1.07 billion in cash upfront to purchase Lumenis' global surgical business. This acquisition allowed Boston Scientific to expand its kidney stone management products globally. Similarly, in June 2020, Olympus Corporation introduced the Soltive Laser System, a new thulium fiber laser application created for soft tissue applications and stone lithotripsy.
Looking for Urolithiasis Management Devices Market Report? Get your free sample PDF with key data & latest trends.
Key questions answered in this report
• How big is the market?
• What is the market growth?
• Which segment accounted for the largest market share?
• Who are the key players in market?
• What are the factors driving the market?